These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6983742)

  • 21. Cell-mediated cytotoxicity to rabbit liver-specific lipoprotein in chronic active hepatitis.
    Ortona L; Laghi V; Cauda R; Nervo P; Mausier ML
    Ric Clin Lab; 1982; 12(3):493-9. PubMed ID: 6182597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An enzyme-linked immunosorbent assay (ELISA) for the detection of IgG and IgM anti-idiotypes directed against anti-HBs molecules.
    Irshad M; Gandhi BM; Acharya SK; Joshi YK; Tandon BN
    J Immunol Methods; 1987 Feb; 96(2):211-7. PubMed ID: 2949020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Decades after recovery from hepatitis B and HBsAg clearance the CD8+ T cell response against HBV core is nearly undetectable.
    Kefalakes H; Jochum C; Hilgard G; Kahraman A; Bohrer AM; El Hindy N; Heinemann FM; Verheyen J; Gerken G; Roggendorf M; Timm J
    J Hepatol; 2015 Jul; 63(1):13-9. PubMed ID: 25646888
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In-vitro cell-mediated cytotoxicity for autologous liver cells in chronic non-A, non-B hepatitis.
    Mondelli M; Alberti A; Tremolada F; Williams R; Eddleston AL; Realdi G
    Clin Exp Immunol; 1986 Jan; 63(1):147-55. PubMed ID: 3082546
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
    Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
    Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunologic reactivity of the skin in chronic hepatitis].
    Fuchs H
    Ann Acad Med Stetin; 1990; 36():61-75. PubMed ID: 2099109
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Direct and serum-induced lymphocytotoxicity against rabbit hepatocytes in chronic active hepatitis.
    Ortona L; Laghi V; Cauda R; Nervo P
    Boll Ist Sieroter Milan; 1981; 60(1):46-51. PubMed ID: 7272012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis C virus infection in anti-HBe-positive HBsAg carriers with chronic liver disease.
    Fiore G; Napoli N; Fera G; Giannelli G; Perricci A; Lonero G; Schiraldi O
    Digestion; 1991; 50(3-4):121-6. PubMed ID: 1667391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis.
    Chu CM; Liaw YF
    Gastroenterology; 1987 Jan; 92(1):220-5. PubMed ID: 3536652
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The immunodominant, Ld-restricted T cell response to hepatitis B surface antigen (HBsAg) efficiently suppresses T cell priming to multiple Dd-, Kd-, and Kb-restricted HBsAg epitopes.
    Schirmbeck R; Stober D; El-Kholy S; Riedl P; Reimann J
    J Immunol; 2002 Jun; 168(12):6253-62. PubMed ID: 12055239
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of hepatitis B surface antigen (HBsAg)-specific cytotoxic T cells in asymptomatic HBsAg carriers.
    Shu PY; Lin MY; Chang C; Hwang LH; Huang JH; Chang TH; Hu C
    J Infect Dis; 1994 Mar; 169(3):633-7. PubMed ID: 7512610
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [A spectrophotometric method of determining the cytotoxic activity of HBsAg-sensitized lymphocytes].
    Derechinskaia EL; Blinova TV
    Lab Delo; 1989; (12):25-9. PubMed ID: 2483196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antigen specific suppressor T cells from chronic hepatitis B virus (HBV) carriers inhibit the responsiveness to HBsAg of allogeneic high-responder lymphocytes.
    Barnaba V; Levrero M; Franco A; Zaccari C; Musca A; Balsano F
    J Clin Lab Immunol; 1985 Mar; 16(3):137-42. PubMed ID: 3162024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunoregulation of the in vitro anti-HBs antibody synthesis in chronic HBsAg carriers and in recently boosted anti-hepatitis B vaccine recipients.
    Barnaba V; Valesini G; Levrero M; Zaccari C; Van Dyke A; Falco M; Musca A; Balsano F
    Clin Exp Immunol; 1985 May; 60(2):259-66. PubMed ID: 3874020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Priming MHC-I-restricted cytotoxic T lymphocyte responses to exogenous hepatitis B surface antigen is CD4+ T cell dependent.
    Wild J; Grusby MJ; Schirmbeck R; Reimann J
    J Immunol; 1999 Aug; 163(4):1880-7. PubMed ID: 10438922
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
    Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
    J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
    [TBL] [Abstract][Full Text] [Related]  

  • 38. T-cell responses to hepatitis B surface antigen in lung transplant recipients.
    Hayney MS; Wiegert NA; Pelsue FL; Fohl RM; Jankowska-Gan E; Love RB; Burlingham WJ
    Pharmacotherapy; 2007 Sep; 27(9):1248-52. PubMed ID: 17723078
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
    Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
    Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Lymphocyte blast transformation to HBsAg and HBcAg in patients with various clinical forms of hepatitis B].
    Savitskiĭ GI; Matveev VA; Mikhaĭlov MI
    Vopr Virusol; 1988; 33(5):559-61. PubMed ID: 3218213
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.